Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | RXRB | P28702 | 2/20 | 0.37 |
| ▸ | RXRG | P48443 | 2/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12361902 | 0.97 | RXRA (0.37) | RXRARXRBRXRGKEAP1NFE2L2 | |
| SCHEMBL12361898 | 0.95 | RXRA (0.39) | RXRARXRBRXRGKEAP1NFE2L2 | |
| SCHEMBL12361900 | 0.92 | NR1H4 (0.40) | RXRARXRBRXRGNR1H4SCD | |
| SCHEMBL12361819 | 0.92 | PSEN1 (0.39) | KEAP1NFE2L2SCD | |
| SCHEMBL12380079 | 0.91 | KEAP1 (0.38) | KEAP1NFE2L2 | |
| SCHEMBL12361955 | 0.90 | NR1H4 (0.40) | RXRARXRBRXRGKEAP1NFE2L2 | |
| SCHEMBL12361957 | 0.90 | NR1H4 (0.40) | RXRARXRBRXRGKEAP1NFE2L2 | |
| SCHEMBL12361903 | 0.90 | NR1H4 (0.40) | RXRARXRBRXRGKEAP1NFE2L2 | |
| SCHEMBL12361913 | 0.90 | NR1H4 (0.40) | RXRARXRBRXRGNR1H4SCD | |
| SCHEMBL12361911 | 0.90 | KEAP1 (0.42) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314240-B2 | Sulfonamide compounds or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | PTGER1, PTGER2, GPER1 | RXRA 2466/4885RXRB 3083/4885RXRG 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.